Home \ Assays \ Complement factor B, Human, ELISA kit
Complement factor B, Human, ELISA kit-0
Catalog # HK367

Complement factor B, Human, ELISA kit

In innate immunity’s arsenal, complement factor B stands as a vigilant defender, crucial for the alternative complement pathway’s activation and microbial destruction.

Read more
Please choose the quantity of items you wish to add to your cart…
Find distributor

Complement factor B (CFB), a key enzyme in innate immunity’s complement system, safeguards against microbial threats and has emerged as a crucial biomarker in clinical settings. Vital for the alternative complement pathway’s activation, CFB’s regulation is critical, particularly for protecting against encapsulated bacterial infections. Clinically, its deficiency links to increased susceptibility to infections such as; pneumococcal and meningococcal infections. Moreover, CFB’s diagnostic potential in pancreatic cancer is noteworthy; when combined with CA19-9 in the ComB-CAN panel, it significantly enhances early detection accuracy. Additionally, CFB may contribute to tumor growth by activating the PI3K-AKT pathway, making it an important focus for cancer screening and research.

Application
The Human Factor B ELISA kit is to be used for the in vitro quantitative determination of Factor B in plasma and serum samples. This kit is intended for laboratory research use only and is not for use in diagnostic or therapeutic procedures.

Principle
The Human Factor B ELISA is a ready-to-use solid-phase enzyme-linked immunosorbent assay based on the sandwich principle with a working time of 3½ hours. The efficient format of a plate with twelve disposable 8-well strips allows free choice of batch size for the assay. Samples and standards are incubated in microtiter wells coated with antibodies recognizing Human Factor B. Biotinylated tracer antibody will bind to the captured Human Factor B. Streptavidin-peroxidase conjugate will bind to the biotinylated tracer antibody. Streptavidin-peroxidase conjugate will react with the substrate, tetramethylbenzidine (TMB). The enzyme reaction is stopped by the addition of oxalic acid. The absorbance at 450 nm is measured with a spectrophotometer. A standard curve is obtained by plotting the absorbance (linear) versus the corresponding concentrations of the Human Factor B standards (log).  The Human Factor B concentration of samples, which are run concurrently with the standards, can be determined from the standard curve.

Linearity
Linearity of 6 EDTA plasma samples was determined. CV of the samples is between 6.0 and 11.4.

Precision and reproducibility
The intra-assay was tested by testing 3 EDTA plasma samples in quadruple and was between 3.4 and 10.7%. The inter-assay was tested by testing 3 EDTA plasma samples in quadruple and was between 2.8 and 9.7%.

Product type
Assays
Amount
1 x 96 det., 2 x 96 det.
Standard range
7.8 to 500 ng/ml
Detection level
7.8 ng/ml
Working volume
100 µl/well
Species
Human
Cross reactivity
Horse – No, Mouse – No, Pig – No, Rat – No
Alias
CFB
Storage and stability
Product should be stored at 4 °C. Under recommended storage conditions, product is stable for at least six months.
Precautions
For research use only. Not for use in or on humans or animals or for diagnostics. It is the responsibility of the user to comply with all local/state and Federal rules in the use of this product. Hycult Biotech is not responsible for any patent infringements that might result with the use of or derivation of this product.
Assay Manual
HK367
367 kb
Safety Data Sheet
SDS - HK367
61 kb

Related products

Calculate your ELISA data easily

With the ELISA calculator you can easily calculate ELISA data. Assayfit Pro helps to perform curve fitting. The calculator generates advanced reports, fit graph, fit parameters and goodness of fit are shown.

Show data entry

Latest Hycult Biotech news

  • New Human Complement Pathway Assays
    We are very proud of our newly developed human classical and alternative complement pathway assays. They are produced in response to a growing demand for quantitative investigation of complement inhibitors or regulators at lower sample dilutions. This development aims to address the issue of false negative results, enabling more accurate and reliable analysis of complement… Read more: New Human Complement Pathway Assays
  • Navigating the pitfalls in complement analysis
    Our colleague Erik Toonen shared his experience on how to analyze complement at the Complement-based Drug Development Summit in Boston in September 11-13th, 2023. He showed valuable insights on analyzing complements. For accurate complement analysis, it is important that not only the correct technique is used but also that pre-analytical sample handling is performed in… Read more: Navigating the pitfalls in complement analysis
  • NEW Human C3d ELISA
    We are happy to introduce our new ELISA (cat.# HK3017) designed to detect human C3d. What sets this assay apart is its utilization of a distinctive neo-epitope capture antibody that selectively targets a specific C3d region of the alpha chain, which is not available in other C3 variants. This way it specifically distinguishes C3d from native C3… Read more: NEW Human C3d ELISA
Contact us